Supersonic flow
Shimadzu's new LCMS-8030 features the most innovative technology found in a commercial tandem quadrupole mass analyzer. Combined with the class-leading Nexera UHPLC, both systems facilitate seamless LC/MS/MS analyses in a high-performance, high-speed flow, steadily and reliably.
Shimadzu's new LCMS-8030 features the most innovative technology found in a commercial tandem quadrupole mass analyzer. Combined with the class-leading Nexera UHPLC, both systems facilitate seamless LC/MS/MS analyses in a high-performance, high-speed flow, steadily and reliably.
The LCMS 8030 instrument features innovative highlights such as an ultrafast pulse counting system, a high speed UF sweeperTM collision cell and a novel RF power supply achieving complete stability within microseconds. These innovations enable this tandem quadrupole mass analyzer to provide the fastest measurements possible, including a scan speed of up to 15,000 u/sec without compromising resolution, sensitivity or mass range. It supports a 15 ms polarity switching time and gives reproducible MRM results with just one millisecond of dwell time, resulting in up to 500 MRM measurements per second.
With the current trend towards higher pressure HPLC and faster operating speeds for greater throughput, the LCMS-8030 is the ideal detector for keeping up with ever-faster chromatographic peaks. Very narrow widths of UHPLC peaks are now easily tamed by the LCMS-8030.For further details please visit www.triplequad.com or www.shimadzu.eu
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
